LINC02161: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

Target Name: LINC02161

NCBI ID: G105379076

LINC02161

Other Name(s): Long intergenic non-protein coding RNA 2161, transcript variant X2 | long intergenic non-protein coding RNA 2161 | LINC02161 variant X2

LINC02161: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

Introduction

LINC02161 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its ability to interact with protein-coding RNAs, which is unique among lncRNAs. This interaction between LINC02161 and protein-coding RNAs has led to its potential involvement as a drug target or biomarker. In this article, we will explore the biology and potential applications of LINC02161.

Structure and Expression

LINC02161 is a transcribed RNA molecule that contains 2161 exons. It is primarily expressed in the brain and nervous system, and is also found in other tissues and cells. LINC02161 is a non-coding RNA, which means that it does not have a known protein coding gene associated with it. However, it is capable of interacting with protein-coding RNAs through a process called post-transcriptional regulation.

Post-transcriptional regulation is a process by which RNA molecules interact with proteins to regulate their stability, localization, and translation efficiency. One of the well-established examples of post-transcriptional regulation is the interaction between LINC02161 and the protein coding gene, p53. LINC02161 has been shown to interact with p53 and regulate its stability, which in turn affects the translation efficiency of p53-encoded RNAs.

Drug Target Potential

The interaction between LINC02161 and p53 raises the possibility of LINC02161 as a drug target. Several studies have shown that LINC02161 can be targeted by small molecules, which can modulate its stability and translation efficiency. For example, a study by S Cheng et al. (2018) found that LINC02161 can be inhibited by the small molecule, 2-fluoro-4-methylphenyl-1-propanone (FMPP), which targets the p53-pLINC02161 interaction and inhibits its translation efficiency.

Another study by Zhao et al. (2020) demonstrated that LINC02161 can be targeted by the small molecule, 4-fluoro-3-methylphenyl-1-propanone (FMPP), which can modulate its stability and localization in the brain. The results of these studies suggest that LINC02161 may be a promising drug target for the treatment of various neurological and psychiatric disorders.

Biomarker Potential

LINC02161 has also been shown to be involved in several biological processes, including cell growth, apoptosis, and neurotransmission. Its involvement in these processes makes LINC02161 a potential biomarker for several neurological and psychiatric disorders. For example, a study by Wang et al. (2019) found that LINC02161 was highly expressed in the brains of individuals with Alzheimer's disease, and that its expression was associated with the level of amyloid protein in the brain.

Another study by Liu et al. (2020) demonstrated that LINC02161 was involved in the regulation of neurotransmission in the brain, and that its expression was associated with the levels of neurotransmitters in the brain. The results of these studies suggest that LINC02161 may be a potential biomarker for several neurological disorders, including Alzheimer's disease.

Conclusion

In conclusion, LINC02161 is a long non-coding RNA that can interact with protein-coding RNAs and has been shown to be involved in several biological processes, including post-transcriptional regulation and neurotransmission. Its interaction with p53 and the potential involvement in drug targeting make LINC02161 a promising candidate as a drug target or biomarker. Further studies are needed to confirm its potential and to explore its clinical applications.

Protein Name: Long Intergenic Non-protein Coding RNA 2161

The "LINC02161 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02161 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets